Detailed Mechanism Funding and Narrative

Years of mechanism: 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 17365
Country/Region: Cameroon
Year: 2018
Main Partner: Metabiota
Main Partner Program: NA
Organizational Type: Private Contractor
Funding Agency: USDOD
Total Funding: $1,314,969 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $409,641
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $0
Care: Pediatric Care and Support (PDCS) $17,314
Laboratory Infrastructure (HLAB) $43,079
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $138,086
Sexual Prevention: Other Sexual Prevention (HVOP) $151,116
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $27,207
Treatment: ARV Drugs (HTXD) $86,571
Treatment: Adult Treatment (HTXS) $424,641
Treatment: Pediatric Treatment (PDTX) $17,314
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_SELF 2019 1,000
HTS_SELF 10-14, Female, Directly-Assisted 2019 20
HTS_SELF 10-14, Female, Unassisted 2019 20
HTS_SELF 10-14, Male, Directly-Assisted 2019 20
HTS_SELF 10-14, Male, Unassisted 2019 20
HTS_SELF 15-19, Female, Directly-Assisted 2019 20
HTS_SELF 15-19, Female, Unassisted 2019 30
HTS_SELF 15-19, Male, Directly-Assisted 2019 20
HTS_SELF 15-19, Male, Unassisted 2019 30
HTS_SELF 20-24, Male, Directly-Assisted 2019 50
HTS_SELF 20-24, Male, Unassisted 2019 50
HTS_SELF 25-29, Female, Directly-Assisted 2019 50
HTS_SELF 25-29, Male, Directly-Assisted 2019 90
HTS_SELF 25-29, Male, Unassisted 2019 90
HTS_SELF 30-34, Male, Directly-Assisted 2019 20
HTS_SELF 30-34, Male, Unassisted 2019 80
HTS_SELF 35-39, Male, Directly-Assisted 2019 20
HTS_SELF 35-39, Male, Unassisted 2019 80
HTS_SELF 40-49, Male, Directly-Assisted 2019 20
HTS_SELF 40-49, Male, Unassisted 2019 70
HTS_SELF 50+, Male, Directly-Assisted 2019 10
HTS_SELF 50+, Male, Unassisted 2019 60
HTS_SELF Directly-Assisted 2019 430
HTS_SELF Unassisted 2019 570
HTS_TST 15-19, Female, Negative 2019 54
HTS_TST 15-19, Male, Negative 2019 54
HTS_TST 20-24, Female, Negative 2019 198
HTS_TST 20-24, Male, Negative 2019 144
HTS_TST 25-29, Female, Negative 2019 144
HTS_TST 25-29, Female, Negative 2019 120
HTS_TST 25-29, Female, Negative 2019 133
HTS_TST 25-29, Female, Negative 2019 546
HTS_TST 25-29, Female, Negative 2019 102
HTS_TST 25-29, Female, Negative 2019 901
HTS_TST 25-29, Female, Negative 2019 682
HTS_TST 25-29, Female, Negative 2019 24
HTS_TST 25-29, Female, Negative 2019 38
HTS_TST 25-29, Male, Negative 2019 180
HTS_TST 25-29, Male, Negative 2019 150
HTS_TST 25-29, Male, Negative 2019 166
HTS_TST 25-29, Male, Negative 2019 683
HTS_TST 25-29, Male, Negative 2019 127
HTS_TST 25-29, Male, Negative 2019 1,200
HTS_TST 25-29, Male, Negative 2019 29
HTS_TST 25-29, Male, Negative 2019 47
HTS_TST 30-34, Female, Negative 2019 162
HTS_TST 30-34, Female, Negative 2019 135
HTS_TST 30-34, Female, Negative 2019 150
HTS_TST 30-34, Female, Negative 2019 615
HTS_TST 30-34, Female, Negative 2019 115
HTS_TST 30-34, Female, Negative 2019 583
HTS_TST 30-34, Female, Negative 2019 425
HTS_TST 30-34, Female, Negative 2019 26
HTS_TST 30-34, Female, Negative 2019 42
HTS_TST 30-34, Male, Negative 2019 54
HTS_TST 30-34, Male, Negative 2019 45
HTS_TST 30-34, Male, Negative 2019 50
HTS_TST 30-34, Male, Negative 2019 205
HTS_TST 30-34, Male, Negative 2019 38
HTS_TST 30-34, Male, Negative 2019 607
HTS_TST 30-34, Male, Negative 2019 9
HTS_TST 30-34, Male, Negative 2019 14
HTS_TST 35-39, Female, Negative 2019 180
HTS_TST 35-39, Female, Negative 2019 150
HTS_TST 35-39, Female, Negative 2019 166
HTS_TST 35-39, Female, Negative 2019 683
HTS_TST 35-39, Female, Negative 2019 127
HTS_TST 35-39, Female, Negative 2019 347
HTS_TST 35-39, Female, Negative 2019 195
HTS_TST 35-39, Female, Negative 2019 29
HTS_TST 35-39, Female, Negative 2019 47
HTS_TST 35-39, Male, Negative 2019 144
HTS_TST 35-39, Male, Negative 2019 120
HTS_TST 35-39, Male, Negative 2019 133
HTS_TST 35-39, Male, Negative 2019 546
HTS_TST 35-39, Male, Negative 2019 102
HTS_TST 35-39, Male, Negative 2019 445
HTS_TST 35-39, Male, Negative 2019 24
HTS_TST 35-39, Male, Negative 2019 38
HTS_TST 40-49, Female, Negative 2019 126
HTS_TST 40-49, Female, Negative 2019 105
HTS_TST 40-49, Female, Negative 2019 116
HTS_TST 40-49, Female, Negative 2019 478
HTS_TST 40-49, Female, Negative 2019 89
HTS_TST 40-49, Female, Negative 2019 330
HTS_TST 40-49, Female, Negative 2019 21
HTS_TST 40-49, Female, Negative 2019 21
HTS_TST 40-49, Female, Negative 2019 33
HTS_TST 40-49, Male, Negative 2019 288
HTS_TST 40-49, Male, Negative 2019 241
HTS_TST 40-49, Male, Negative 2019 266
HTS_TST 40-49, Male, Negative 2019 1,093
HTS_TST 40-49, Male, Negative 2019 204
HTS_TST 40-49, Male, Negative 2019 564
HTS_TST 40-49, Male, Negative 2019 47
HTS_TST 40-49, Male, Negative 2019 76
HTS_TST 50+, Female, Negative 2019 54
HTS_TST 50+, Male, Negative 2019 216
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 30,226
HTS_TST Service Delivery Point (Community) Index Mod: 10-14, Female, Negative 2019 32
HTS_TST Service Delivery Point (Community) Index Mod: 10-14, Male, Negative 2019 48
HTS_TST Service Delivery Point (Community) Index Mod: 15-19, Female, Negative 2019 38
HTS_TST Service Delivery Point (Community) Index Mod: 15-19, Male, Negative 2019 38
HTS_TST Service Delivery Point (Community) Index Mod: 20-24, Female, Negative 2019 140
HTS_TST Service Delivery Point (Community) Index Mod: 20-24, Male, Negative 2019 102
HTS_TST Service Delivery Point (Community) Index Mod: 50+, Female, Negative 2019 38
HTS_TST Service Delivery Point (Community) Index Mod: 50+, Male, Negative 2019 153
HTS_TST Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative 2019 205
HTS_TST Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative 2019 205
HTS_TST Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative 2019 751
HTS_TST Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative 2019 546
HTS_TST Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative 2019 205
HTS_TST Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative 2019 820
HTS_TST Service Delivery Point (Facility) ANC: 10-14, Negative 2019 7
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2019 247
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2019 576
HTS_TST Service Delivery Point (Facility) Index: <1, Negative 2019 23
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2019 646
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 62
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 38
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 45
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 45
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 165
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 120
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 45
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 180
HTS_TST Service Delivery Point (Facility) Inpatient: <1, Negative 2019 2
HTS_TST Service Delivery Point (Facility) Inpatient: 1-9, Negative 2019 15
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2019 4
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2019 3
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 50
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2019 50
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 183
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2019 133
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2019 50
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2019 199
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2019 377
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2019 77
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2019 70
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 323
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 160
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 1,030
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 1,045
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2019 485
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2019 547
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2019 453
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2019 9
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2019 12
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 9
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 9
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 32
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 24
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2019 9
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 35
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2019 14
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2019 14
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2019 52
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2019 38
HTS_TST Service Delivery Point (Facility) VCT: 50+, Female, Negative 2019 14
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2019 57
HTS_TST Service Delivery Point (Facility)Other PITC: <1, Negative 2019 32
HTS_TST_POS 15-19, Female, Positive 2019 4
HTS_TST_POS 20-24, Female, Positive 2019 8
HTS_TST_POS 20-24, Male, Positive 2019 4
HTS_TST_POS 25-29, Female, Positive 2019 17
HTS_TST_POS 25-29, Female, Positive 2019 39
HTS_TST_POS 25-29, Female, Positive 2019 12
HTS_TST_POS 25-29, Female, Positive 2019 46
HTS_TST_POS 25-29, Female, Positive 2019 25
HTS_TST_POS 25-29, Female, Positive 2019 58
HTS_TST_POS 25-29, Female, Positive 2019 21
HTS_TST_POS 25-29, Female, Positive 2019 18
HTS_TST_POS 25-29, Female, Positive 2019 2
HTS_TST_POS 25-29, Male, Positive 2019 33
HTS_TST_POS 30-34, Female, Positive 2019 4
HTS_TST_POS 30-34, Female, Positive 2019 10
HTS_TST_POS 30-34, Female, Positive 2019 3
HTS_TST_POS 30-34, Female, Positive 2019 11
HTS_TST_POS 30-34, Female, Positive 2019 6
HTS_TST_POS 30-34, Female, Positive 2019 65
HTS_TST_POS 30-34, Female, Positive 2019 12
HTS_TST_POS 30-34, Female, Positive 2019 4
HTS_TST_POS 30-34, Female, Positive 2019 1
HTS_TST_POS 30-34, Male, Positive 2019 46
HTS_TST_POS 30-34, Male, Positive 2019 107
HTS_TST_POS 30-34, Male, Positive 2019 32
HTS_TST_POS 30-34, Male, Positive 2019 126
HTS_TST_POS 30-34, Male, Positive 2019 69
HTS_TST_POS 30-34, Male, Positive 2019 50
HTS_TST_POS 30-34, Male, Positive 2019 49
HTS_TST_POS 30-34, Male, Positive 2019 6
HTS_TST_POS 35-39, Female, Positive 2019 4
HTS_TST_POS 35-39, Female, Positive 2019 10
HTS_TST_POS 35-39, Female, Positive 2019 3
HTS_TST_POS 35-39, Female, Positive 2019 11
HTS_TST_POS 35-39, Female, Positive 2019 6
HTS_TST_POS 35-39, Female, Positive 2019 36
HTS_TST_POS 35-39, Female, Positive 2019 12
HTS_TST_POS 35-39, Female, Positive 2019 4
HTS_TST_POS 35-39, Female, Positive 2019 1
HTS_TST_POS 35-39, Male, Positive 2019 17
HTS_TST_POS 35-39, Male, Positive 2019 39
HTS_TST_POS 35-39, Male, Positive 2019 12
HTS_TST_POS 35-39, Male, Positive 2019 46
HTS_TST_POS 35-39, Male, Positive 2019 25
HTS_TST_POS 35-39, Male, Positive 2019 38
HTS_TST_POS 35-39, Male, Positive 2019 18
HTS_TST_POS 35-39, Male, Positive 2019 2
HTS_TST_POS 40-49, Female, Positive 2019 29
HTS_TST_POS 40-49, Female, Positive 2019 68
HTS_TST_POS 40-49, Female, Positive 2019 20
HTS_TST_POS 40-49, Female, Positive 2019 80
HTS_TST_POS 40-49, Female, Positive 2019 44
HTS_TST_POS 40-49, Female, Positive 2019 36
HTS_TST_POS 40-49, Female, Positive 2019 31
HTS_TST_POS 40-49, Female, Positive 2019 4
HTS_TST_POS 40-49, Male, Positive 2019 17
HTS_TST_POS 40-49, Male, Positive 2019 39
HTS_TST_POS 40-49, Male, Positive 2019 12
HTS_TST_POS 40-49, Male, Positive 2019 46
HTS_TST_POS 40-49, Male, Positive 2019 25
HTS_TST_POS 40-49, Male, Positive 2019 77
HTS_TST_POS 40-49, Male, Positive 2019 18
HTS_TST_POS 40-49, Male, Positive 2019 2
HTS_TST_POS 50+, Male, Positive 2019 13
HTS_TST_POS Service Delivery Point (Community) Index Mod: 15-19, Female, Positive 2019 6
HTS_TST_POS Service Delivery Point (Community) Index Mod: 20-24, Female, Positive 2019 13
HTS_TST_POS Service Delivery Point (Community) Index Mod: 20-24, Male, Positive 2019 6
HTS_TST_POS Service Delivery Point (Community) Index Mod: 50+, Male, Positive 2019 19
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive 2019 11
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive 2019 23
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive 2019 11
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive 2019 34
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2019 64
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2019 10
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 20
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 10
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2019 29
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 1-9, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2019 6
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Male, Positive 2019 9
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 1-9, Positive 2019 23
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2019 54
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2019 13
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2019 38
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2019 42
HTS_TST_POS Service Delivery Point (Facility) Pediatric : <5 Positive 2019 9
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Female, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2019 9
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Male, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Male, Positive 2019 13
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Male, Positive 2019 2
PMTCT_ART Already on ART at beginning of current pregnancy 2019 115
PMTCT_ART New on ART 2019 39
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 154
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 2,308
PMTCT_EID By infants who received a virologic test within 2 months of birth 2019 111
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 28
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 139
PMTCT_EID Sum of Infant Age disaggregates 2019 139
PMTCT_STAT 25-29, Female 2019 741
PMTCT_STAT 25-29, Female, Known at Entry Positive 2019 31
PMTCT_STAT 25-29, Female, Newly Identified Negative 2019 689
PMTCT_STAT 25-29, Female, Newly Identified Positive 2019 21
PMTCT_STAT 30-34, Female 2019 480
PMTCT_STAT 30-34, Female, Known at Entry Positive 2019 37
PMTCT_STAT 30-34, Female, Newly Identified Negative 2019 431
PMTCT_STAT 30-34, Female, Newly Identified Positive 2019 12
PMTCT_STAT 35-39, Female 2019 211
PMTCT_STAT 35-39, Female, Known at Entry Positive 2019 5
PMTCT_STAT 35-39, Female, Newly Identified Negative 2019 194
PMTCT_STAT 35-39, Female, Newly Identified Positive 2019 12
PMTCT_STAT 40-49, Female 2019 27
PMTCT_STAT 40-49, Female, Known at Entry Positive 2019 5
PMTCT_STAT 40-49, Female, Newly Identified Negative 2019 22
PMTCT_STAT By Age (Numerator): 15-19 2019 237
PMTCT_STAT By Age (Numerator): 20-24 2019 611
PMTCT_STAT By Number of known positives: 20-24 2019 26
PMTCT_STAT By Number of new negative: 15-19 2019 237
PMTCT_STAT By Number of new negative: 20-24 2019 581
PMTCT_STAT By Number of new positives: 20-24 2019 4
PMTCT_STAT Number of new ANC and L&D clients 2019 2,429
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 2,308
PMTCT_STAT_den 25-29, Female 2019 777
PMTCT_STAT_den 30-34, Female 2019 486
PMTCT_STAT_den 35-39, Female 2019 219
PMTCT_STAT_den 40-49, Female 2019 24
PMTCT_STAT_den By Age (Denominator): <15-19 2019 291
PMTCT_STAT_den By Age (Denominator): 20-24 2019 632
PP_PREV 25-29, Female 2019 330
PP_PREV 25-29, Male 2019 1,245
PP_PREV 30-34, Female 2019 130
PP_PREV 30-34, Male 2019 650
PP_PREV 35-39, Female 2019 130
PP_PREV 35-39, Male 2019 520
PP_PREV 40-49, Female 2019 130
PP_PREV 40-49, Male 2019 325
PP_PREV Age/sex: 10-14 Female 2019 260
PP_PREV Age/sex: 10-14 Male 2019 13
PP_PREV Age/sex: 15-19 Female 2019 650
PP_PREV Age/sex: 15-19 Male 2019 65
PP_PREV Age/sex: 20-24 Female 2019 650
PP_PREV Age/sex: 20-24 Male 2019 774
PP_PREV Age/sex: 50+ Female 2019 65
PP_PREV Age/sex: 50+ Male 2019 564
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2019 6,501
PP_PREV Sum of Age/Sex disaggregates 2019 3,041
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 127
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 117
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 244
TB_PREV By Age/Sex (Numerator): <15, Female 2019 8
TB_PREV By Age/Sex (Numerator): <15, Male 2019 10
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 213
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 308
TB_PREV IPT, Life-long ART, Already, Positive 2019 458
TB_PREV IPT, Life-long ART, New, Positive 2019 81
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 539
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 539
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 8
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 10
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 213
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 309
TB_PREV_den IPT, Life-long ART, Already, Positive 2019 458
TB_PREV_den IPT, Life-long ART, New, Positive 2019 81
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 9
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 234
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 11
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 337
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 591
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 657
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 10
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 259
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 12
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 376
TX_CURR 25-29, Female, Positive 2019 541
TX_CURR 25-29, Male, Positive 2019 232
TX_CURR 30-34, Female, Positive 2019 772
TX_CURR 30-34, Male, Positive 2019 309
TX_CURR 35-39, Female, Positive 2019 849
TX_CURR 35-39, Male, Positive 2019 386
TX_CURR 40-49, Female, Positive 2019 1,389
TX_CURR 40-49, Male, Positive 2019 927
TX_CURR Age/Sex: <1 2019 2
TX_CURR Age/Sex: <1-9 2019 121
TX_CURR Age/Sex: 10-14 Female 2019 23
TX_CURR Age/Sex: 10-14 Male 2019 28
TX_CURR Age/Sex: 15-19 Female 2019 77
TX_CURR Age/Sex: 15-19 Male 2019 77
TX_CURR Age/Sex: 20-24 Female 2019 232
TX_CURR Age/Sex: 20-24 Male 2019 77
TX_CURR Age/Sex: 50+ Female 2019 1,081
TX_CURR Age/Sex: 50+ Male 2019 772
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 7,895
TX_CURR Sum of age/sex disaggregates 2019 154
TX_NEW 25-29, Female, Positive 2019 292
TX_NEW 25-29, Male, Positive 2019 83
TX_NEW 30-34, Female, Positive 2019 250
TX_NEW 30-34, Male, Positive 2019 104
TX_NEW 35-39, Female, Positive 2019 167
TX_NEW 35-39, Male, Positive 2019 146
TX_NEW 40-49, Female, Positive 2019 250
TX_NEW 40-49, Male, Positive 2019 210
TX_NEW By Age/Sex: <1 2019 4
TX_NEW By Age/Sex: 1-9 2019 4
TX_NEW By Age/Sex: 10-14 Female 2019 65
TX_NEW By Age/Sex: 10-14 Male 2019 7
TX_NEW By Age/Sex: 15-19 Female 2019 42
TX_NEW By Age/Sex: 20-24 Female 2019 167
TX_NEW By Age/Sex: 20-24 Male 2019 42
TX_NEW By Age/Sex: 50+ Female 2019 167
TX_NEW By Age/Sex: 50+ Male 2019 167
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 2,167
TX_NEW Pregnancy status 2019 125
TX_NEW Sum of Age/Sex disaggregates 2019 657
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 6,528
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 65
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2019 65
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 65
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2019 65
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 2,872
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 261
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 2,873
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 262
TX_PVLS_den Denominator: Indication: Routine 2019 5,875
TX_PVLS_den Denominator: Indication: Targeted 2019 653
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 25
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 17
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 1,088
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 783
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 1,944
TX_RET Numerator by Status: Breastfeeding 2019 31
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 2,162
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 28
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 19
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 1,145
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 935
TX_RET_den Denominator by Status: Breastfeeding 2019 35
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 6,316
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 63
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 126
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 3,790
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 2,337
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 17
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 3
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 20
TX_TB_den Life-long ART, Already, TB Screen - Positive, Positive 2019 1,263
TX_TB_den Life-long ART, New, TB Screen - Negative, Positive 2019 63
TX_TB_den Life-long ART, New, TB Screen - Positive, Positive 2019 4,990
Cross Cutting Budget Categories and Known Amounts Total: $385,611
Gender: Gender Based Violence (GBV) $50,000
GBV Prevention
Post GBV Care
Water $25,000
Food and Nutrition: Policy, Tools, and Service Delivery $10,000
Condoms: Policy, Tools, and Services $47,223
Adolescent Girls and Young Women (AGYW) $106,926
Human Resources for Health $146,462